Critical Contrast: Black Diamond Therapeutics (NASDAQ:BDTX) & Evaxion A/S (NASDAQ:EVAX)

Evaxion A/S (NASDAQ:EVAX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

Evaxion A/S has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.31, indicating that its share price is 231% more volatile than the S&P 500.

Valuation & Earnings

This table compares Evaxion A/S and Black Diamond Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.49 million	3.58	-$7.71 million	($1.21)	-2.66
Black Diamond Therapeutics	N/A	N/A	$22.37 million	($0.75)	-2.57

Black Diamond Therapeutics has lower revenue, but higher earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Evaxion A/S and Black Diamond Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1	0	5	0	2.67
Black Diamond Therapeutics	1	2	8	0	2.64

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 241.61%. Black Diamond Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 431.09%. Given Black Diamond Therapeutics’ higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Evaxion A/S.

Profitability

This table compares Evaxion A/S and Black Diamond Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Insider & Institutional Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Evaxion A/S on 9 of the 12 factors compared between the two stocks.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.